TREVI THERAPEUTICS INC's ticker is TRVI and the CUSIP is 89532M101. A total of 33 filers reported holding TREVI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is - and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $203,830 | -8.8% | 93,500 | 0.0% | 0.07% | -1.4% |
| Q2 2023 | $223,465 | +29.2% | 93,500 | 0.0% | 0.07% | +25.4% |
| Q1 2023 | $172,975 | -4.1% | 93,500 | 0.0% | 0.06% | -6.3% |
| Q4 2022 | $180,455 | +26.2% | 93,500 | 0.0% | 0.06% | +16.7% |
| Q3 2022 | $143,000 | -45.4% | 93,500 | 0.0% | 0.05% | -41.9% |
| Q2 2022 | $262,000 | +21.3% | 93,500 | -5.1% | 0.09% | +38.8% |
| Q1 2022 | $216,000 | +881.8% | 98,500 | +245.6% | 0.07% | +857.1% |
| Q4 2021 | $22,000 | -56.9% | 28,500 | -21.9% | 0.01% | -58.8% |
| Q3 2021 | $51,000 | -42.0% | 36,500 | -7.6% | 0.02% | -39.3% |
| Q2 2021 | $88,000 | -15.4% | 39,500 | +2.6% | 0.03% | -20.0% |
| Q1 2021 | $104,000 | +285.2% | 38,500 | +234.8% | 0.04% | +250.0% |
| Q4 2020 | $27,000 | – | 11,500 | – | 0.01% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| NEA Management Company, LLC | 11,370,376 | $24,787,420 | 1.91% |
| Fairmount Funds Management LLC | 5,163,287 | $11,255,966 | 1.35% |
| Opaleye Management Inc. | 1,705,900 | $3,718,862 | 1.21% |
| Frazier Life Sciences Management, L.P. | 6,881,090 | $15,000,776 | 1.00% |
| VR Adviser, LLC | 3,422,397 | $7,460,825 | 0.78% |
| SILVERARC CAPITAL MANAGEMENT, LLC | 927,415 | $2,021,765 | 0.61% |
| Rubric Capital Management LP | 5,684,420 | $12,392,036 | 0.46% |
| Tejara Capital Ltd | 180,227 | $392,895 | 0.22% |
| PFS Partners, LLC | 100,000 | $218,000 | 0.19% |
| WealthTrust Axiom LLC | 93,500 | $203,830 | 0.07% |